排序方式: 共有7条查询结果,搜索用时 15 毫秒
1
1.
2.
Kane Jeremy C. Sharma Anjali Murray Laura K. Chander Geetanjali Kanguya Tukiya Skavenski Stephanie Chitambi Chipo Lasater Molly E. Paul Ravi Cropsey Karen Inoue Sachi Bosomprah Samuel Danielson Carla Kmett Chipungu Jenala Simenda Francis Vinikoor Michael J. 《AIDS and behavior》2022,26(2):523-536
AIDS and Behavior - This randomized controlled trial tested the efficacy of a multi-session, evidence-based, lay counselor-delivered transdiagnostic therapy, the Common Elements Treatment Approach... 相似文献
3.
Elizabeth Zaniewski Cam H Dao Ostinelli Frdrique Chammartin Nicola Maxwell Mary‐Ann Davies Jonathan Euvrard Janneke van Dijk Samuel Bosomprah Sam Phiri Frank Tanser Nosisa Sipambo Josephine Muhairwe Geoffrey Fatti Hans Prozesky Robin Wood Nathan Ford Matthew P Fox Matthias Egger 《Journal of the International AIDS Society》2020,23(7)
4.
Natasha Makabilo Laban Martin Rhys Goodier Samuel Bosomprah Michelo Simuyandi Caroline Chisenga Obvious Nchimunya Chilyabanyama Roma Chilengi 《Viruses》2022,14(3)
Cellular immunity against rotavirus in children is incompletely understood. This review describes the current understanding of T-cell immunity to rotavirus in children. A systematic literature search was conducted in Embase, MEDLINE, Web of Science, and Global Health databases using a combination of “t-cell”, “rotavirus” and “child” keywords to extract data from relevant articles published from January 1973 to March 2020. Only seventeen articles were identified. Rotavirus-specific T-cell immunity in children develops and broadens reactivity with increasing age. Whilst occurring in close association with antibody responses, T-cell responses are more transient but can occur in absence of detectable antibody responses. Rotavirus-induced T-cell immunity is largely of the gut homing phenotype and predominantly involves Th1 and cytotoxic subsets that may be influenced by IL-10 Tregs. However, rotavirus-specific T-cell responses in children are generally of low frequencies in peripheral blood and are limited in comparison to other infecting pathogens and in adults. The available research reviewed here characterizes the T-cell immune response in children. There is a need for further research investigating the protective associations of rotavirus-specific T-cell responses against infection or vaccination and the standardization of rotavirus-specific T-cells assays in children. 相似文献
5.
6.
7.
Nebie I Diarra A Ouedraogo A Soulama I Bougouma EC Tiono AB Konate AT Chilengi R Theisen M Dodoo D Remarque E Bosomprah S Milligan P Sirima SB 《Infection and immunity》2008,76(2):759-766
There is longstanding evidence that immunoglobulin G (IgG) has a role in protection against clinical malaria, and human antibodies of the cytophilic subclasses are thought to be particularly critical in this respect. In this cohort study, 286 Burkinabè children 6 months to 15 years old were kept under malaria surveillance in order to assess the protective role of antibody responses against four antigens which are currently being evaluated as vaccine candidates: apical membrane antigen 1 (AMA1), merozoite surface protein 1-19 (MSP1-19), MSP3, and glutamate-rich protein (GLURP). Total IgG, IgM, and IgG subclass responses were measured just before the malaria transmission season. The incidence of malaria was 2.4 episodes per child year of risk. After adjusting for the confounding effects of age, the level of total IgG to GLURP was strongly associated with reduced malaria incidence (incidence rate ratio associated with a doubling of total IgG, 0.79; 95% confidence interval, 0.66 to 0.94; P = 0.009.); there was a borderline statistically significant association between the level of total IgG to MSP3 and malaria incidence and no evidence of an association for total IgG to AMA1 and to MSP1-19. Of the IgG subclass responses studied, only IgG3 and IgG4 against GLURP and IgG1 against AMA1 were associated with reduced risk of clinical malaria. There was no evidence of an interaction between responses to AMA1 and baseline parasitemia in their effects on malaria incidence. Currently included in malaria vaccine formulations for clinical trials in humans, these blood-stage antigens, AMA1 and GLURP, offer good prospects for malaria vaccine development. 相似文献
1